Schölmerich J, Zimmermann U, Köttgen E, Volk B A, Ehlers S, Gerok W
Klin Wochenschr. 1987 Jul 15;65(14):634-8. doi: 10.1007/BF01875497.
The concentrations of several proteases and antiproteases known to be present in ascites were tested in plasma and ascitic fluid with regard to their ability to separate ascites according to malignant or nonmalignant disease. Seventeen patients with proven malignant ascites and 37 with ascites due to liver cirrhosis were included. Activities of plasminogen, alpha 2-antiplasmin, antithrombin-III, and factor V, and the concentration of alpha 1-protease inhibitor were significantly higher in the plasma of patients with malignant ascites than in cirrhotic patients. Fibronectin, plasminogen, alpha 2-macroglobulin, alpha 1-protease inhibitor, antithrombin-III, and albumin revealed higher concentrations or activities in malignant ascites than in cirrhotic ascites. Due to a wide variation of most parameters, only fibronectin, antithrombin III, and alpha 1-protease inhibitor in ascites had a sensitivity and specificity higher than 90% for malignant ascites. When the specific protein/albumin ratio was used, only the accuracy of fibronectin was increased reaching a sensitivity and specificity of 100%. The plasma/ascites gradients of the proteins assessed differed significantly, that of fibronectin being much higher (22 +/- 7) than that of all other proteins. In malignant ascites fibronectin concentration was only correlated with alpha 1-protease inhibitor concentration but not with the concentration or activity of all other proteins, while in cirrhotic ascites most proteins revealed a positive correlation. The determination of the fibronectin concentration or the fibronectin/albumin ratio in ascites can differentiate malignant and nonmalignant ascites. All other proteases and antiproteases assessed are of lesser value for this purpose, although most are significantly increased in ascites and plasma of patients with malignant disorders.
针对几种已知存在于腹水中的蛋白酶和抗蛋白酶,检测其在血浆和腹水中根据恶性或非恶性疾病区分腹水的能力。纳入了17例确诊为恶性腹水的患者和37例肝硬化腹水患者。恶性腹水患者血浆中纤溶酶原、α2-抗纤溶酶、抗凝血酶III和因子V的活性以及α1-蛋白酶抑制剂的浓度显著高于肝硬化患者。与肝硬化腹水相比,恶性腹水中纤连蛋白、纤溶酶原、α2-巨球蛋白、α1-蛋白酶抑制剂、抗凝血酶III和白蛋白的浓度或活性更高。由于大多数参数变化范围广,腹水中只有纤连蛋白、抗凝血酶III和α1-蛋白酶抑制剂对恶性腹水的敏感性和特异性高于90%。当使用特定蛋白/白蛋白比值时,只有纤连蛋白的准确性提高,敏感性和特异性达到100%。所评估蛋白质的血浆/腹水梯度差异显著,纤连蛋白的梯度(22±7)远高于所有其他蛋白质。在恶性腹水中,纤连蛋白浓度仅与α1-蛋白酶抑制剂浓度相关,与所有其他蛋白质的浓度或活性无关,而在肝硬化腹水中,大多数蛋白质呈正相关。测定腹水中纤连蛋白浓度或纤连蛋白/白蛋白比值可区分恶性和非恶性腹水。尽管大多数在恶性疾病患者的腹水和血浆中显著升高,但所评估的所有其他蛋白酶和抗蛋白酶在此目的上价值较小。